The announcement of five new prescribing-enabled Pharmacy First pathways is undoubtedly a landmark moment for community pharmacy.
For years, the profession has argued that pharmacists are an underutilised clinical resource. The introduction of independent prescribing within nationally commissioned services represents a significant step towards making full use of our clinical skills and improving patient access to timely care.
The opportunity is substantial.
Patients increasingly want healthcare that is accessible, convenient and available closer to home. Community pharmacies are uniquely placed to provide that care. The addition of prescribing capability allows pharmacists to manage more patients from consultation through to treatment, reducing friction within the system and helping relieve pressure on general practice and urgent care services.
The clinical areas selected are sensible starting points. They represent common conditions that patients frequently seek help for and where appropriately trained pharmacist prescribers can make a meaningful contribution. Combined with prescribing within the existing Pharmacy First pathways and contraception services, this begins to create a more comprehensive clinical offer within community pharmacy.
However, whilst the strategic direction is unquestionably right, the current model falls short in several important areas.
The first concern is funding.
There is a tendency within healthcare reform to focus on service specifications and activity projections whilst underestimating the real-world cost of delivery. NHS England has outlined an ambition that prescribing pathways could eventually generate between two and three million consultations annually. That is an exciting vision. The question is whether the funding available is genuinely aligned with that ambition.
The one-off setup payment, monthly infrastructure payment and consultation fee provide a payment mechanism, but they do not necessarily cover the full costs that contractors will incur. New prescribing services bring additional governance requirements, indemnity considerations, clinical supervision, workforce costs, digital infrastructure and electronic prescribing dependencies. Many contractors will rightly undertake detailed commercial modelling before deciding whether participation is viable.
My concern is that too much of the available investment risks being absorbed into fixed implementation and IT costs rather than directly supporting patient-facing clinical capacity.
The second concern is workforce development.
Prescribing is often discussed as though the challenge will naturally solve itself as newly qualified pharmacists enter the profession with prescribing qualifications. That would be a mistake.
Community pharmacy already employs thousands of experienced pharmacists who are not independent prescribers. If we are serious about transforming care, our first priority should be rapidly supporting and developing this existing workforce alongside newly qualified prescribers.
Without that investment, there is a real danger that we create a two-tier profession: pharmacist prescribers and pharmacist non-prescribers. That would be bad for workforce morale, recruitment and retention, and ultimately service growth.
Equally important is ensuring that pharmacist prescribers have access to appropriate supervision, peer support, clinical networks and training opportunities. Prescribing qualifications alone do not create confident clinicians. The surrounding governance and support structures are just as important as the qualification itself.
“The future of community pharmacy should not be defined by whether a pharmacist can prescribe, but by how quickly we support every pharmacist to operate at the top of their licence.”
Despite these challenges, I remain optimistic.
The profession has consistently demonstrated its ability to deliver when trusted with greater responsibility. Pharmacy First has shown what community pharmacy can achieve when barriers are removed and patients are empowered to use their local pharmacy as a first point of contact.
Independent prescribing is the logical next step in that journey.
The ultimate prize is not simply a new service. It is the creation of a sustainable clinical model for community pharmacy that makes full use of the skills of pharmacists, improves patient outcomes and strengthens primary care.
The opportunity is real. But to realise its full potential, we need sufficient investment, sensible implementation and a commitment to develop the whole workforce, not just the next generation of prescribers.
If we get those foundations right, prescribing could become one of the most important advances in community pharmacy for a generation.
